Literature DB >> 31645124

Ginsenoside Rh2 Suppresses Breast Cancer Cell Proliferation by Epigenetically Regulating the Long Noncoding RNA C3orf67-AS1.

Dawoon Jeong1, Juyeon Ham1, Sungbin Park1, Hyeon Woo Kim1, Heejoo Kim1, Hwee Won Ji1, Sun Jung Kim1.   

Abstract

Ginsenoside Rh2, a major bioactive ingredient abundant in red ginseng, has an antiproliferative effect on various cancer cells. In this study, we report a novel long noncoding RNA, C3orf67-AS1, which was identified as being hypermethylated at a CpG site of the promoter by Rh2 in MCF-7 cancer cells. Rh2-induced hypermethylation was responsible for the lower gene expression; the expression was recovered following treatment with a methyltransferase inhibitor, 5-aza-2'-deoxycytidine. When C3orf67-AS1 was downregulated by a siRNA, the cell growth rate was decreased, demonstrating the RNA's oncogenic activity. Accordingly, breast cancer patients showed a lower methylation and higher expression level of C3orf67-AS1. Within 800 kb flanking C3orf67-AS1 on the chromosome, eight genes were found, and four genes including C3orf67 (the sense strand gene of C3orf67-AS1) were downregulated by Rh2. In particular, C3orf67 was downregulated when C3orf67-AS1 was suppressed by a siRNA; however, the expression of C3orf67-AS1 was not affected by C3orf67. Taken together, this study identifies a novel noncoding RNA, C3orf67-AS1, of which the expression could be suppressed by Rh2 via promoter methylation, thereby mediating the anti-proliferative effect of the ginsenoside.

Entities:  

Keywords:  Breast Cancer; CpG Methylation; Ginsenoside Rh2; Long Noncoding RNA; MCF-7

Mesh:

Substances:

Year:  2019        PMID: 31645124     DOI: 10.1142/S0192415X19500848

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  7 in total

1.  Study on the Mechanism of Ginseng in the Treatment of Lung Adenocarcinoma Based on Network Pharmacology.

Authors:  Qiu-Yue Li; Cheng-Zhi Hou; Li-Ping Yang; Xue-Lei Chu; Yuan Wang; Ping Zhang; Yong Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2020-07-31       Impact factor: 2.629

2.  Mechanism-Based Pharmacokinetic Model for the Deglycosylation Kinetics of 20(S)-Ginsenosides Rh2.

Authors:  Hong-Can Ren; Jian-Guo Sun; Ji-Ye A; Sheng-Hua Gu; Jian Shi; Feng Shao; Hua Ai; Jing-Wei Zhang; Ying Peng; Bei Yan; Qing Huang; Lin-Sheng Liu; Yang Sai; Guang-Ji Wang; Cheng-Guang Yang
Journal:  Front Pharmacol       Date:  2022-05-25       Impact factor: 5.988

3.  Ginsenoside Rh2 upregulates long noncoding RNA STXBP5-AS1 to sponge microRNA-4425 in suppressing breast cancer cell proliferation.

Authors:  Jae Eun Park; Hyeon Woo Kim; Sung Hwan Yun; Sun Jung Kim
Journal:  J Ginseng Res       Date:  2021-08-27       Impact factor: 6.060

4.  Ginsenoside Rh2 reduces m6A RNA methylation in cancer via the KIF26B-SRF positive feedback loop.

Authors:  Chunmei Hu; Linhan Yang; Yi Wang; Shijie Zhou; Jing Luo; Yi Gu
Journal:  J Ginseng Res       Date:  2021-05-25       Impact factor: 6.060

Review 5.  Targeting Epigenetic Regulatory Enzymes for Cancer Therapeutics: Novel Small-Molecule Epidrug Development.

Authors:  Ye Jin; Tianjia Liu; Haoming Luo; Yangyang Liu; Da Liu
Journal:  Front Oncol       Date:  2022-03-28       Impact factor: 6.244

6.  Ginseng berry concentrate prevents colon cancer via cell cycle, apoptosis regulation, and inflammation-linked Th17 cell differentiation.

Authors:  C-Z Wang; C Wan; Y Luo; C-F Zhang; Q-H Zhang; L Chen; C W Park; S H Kim; Z Liu; M Lager; M Xu; L Hou; C-S Yuan
Journal:  J Physiol Pharmacol       Date:  2021-08-06       Impact factor: 3.011

Review 7.  PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential.

Authors:  Hai Huang; Mee-Hyun Lee; Kangdong Liu; Zigang Dong; Zeayoung Ryoo; Myoung Ok Kim
Journal:  Cancers (Basel)       Date:  2021-05-06       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.